source
- Cancer and immune-focused biotech firms capture over $3.9 billion of H1 2026 venture capitalBioPharma Dive data show that cancer and immune disease biotech companies accounted for more than 40% of the biotech firms receiving venture funding in the first half of 2026. Of the roughly $9 bi…
- Gene-editing biotech Scribe Therapeutics files for Nasdaq IPOScribe Therapeutics, a California-based biotechnology startup developing genetic medicines for cardiometabolic disorders, announced plans to go public on the Nasdaq under the ticker SCTX. The comp…